The proposed bill, SB 119, seeks to enhance Medicaid pharmaceutical services by allowing pharmacists to dispense brand name drugs to Medicaid beneficiaries when these drugs are included on the Department of Health and Human Services' preferred drug list. This amendment modifies existing law, specifically RSA 126-A:3, V, which previously prioritized generic drug coverage unless a brand name was deemed medically necessary by a prescribing provider. The bill also introduces a new provision permitting pharmacists to dispense Ivermectin under a standing order from authorized healthcare providers without requiring a prior prescription, while ensuring adherence to safety protocols.

Additionally, the bill outlines responsibilities and protections for pharmacists and healthcare providers involved in dispensing Ivermectin, including patient screening protocols and documentation requirements. It prohibits financial incentives that could influence prescribing practices and protects healthcare professionals from disciplinary action for a pharmacist's failure to follow standing orders, provided guidelines are met. The fiscal impact of the bill is projected to yield net savings for the Medicaid program, with estimated savings of $1.1 million in FY 2026, $3.4 million in FY 2027, and $4.5 million in FY 2028, primarily through increased rebate revenue from manufacturers. The act is set to take effect on July 1, 2025.

Statutes affected:
Introduced: 126-A:3
As Amended by the House: 126-A:3